The stock of Opus Genetics Inc (NASDAQ: IRD) has increased by 17.58 when compared to last closing price of 0.99.Despite this, the company has seen a gain of 14.64% in its stock price over the last five trading days. globenewswire.com reported 2025-06-02 that Study met primary endpoint of ≥15-letter (≥3-line) gain in mesopic low contrast distance visual acuity in comparison to placebo Phase 3 study showed patient-reported functional benefit in treating significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision, a condition with no current FDA-approved therapies Safety profile consistent with previous studies, with no new safety signals identified No evidence of tachyphylaxis was observed in this study over the 6-week period Study was conducted under FDA Special Protocol Assessment and Fast-Track Designation RESEARCH TRIANGLE PARK, N.C., June 02, 2025 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced positive topline results from LYNX-2, a pivotal Phase 3 clinical trial evaluating Phentolamine Ophthalmic Solution 0.75% for the treatment of significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision.
Is It Worth Investing in Opus Genetics Inc (NASDAQ: IRD) Right Now?
The 36-month beta value for IRD is at -0.00. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for IRD is 39.42M, and currently, shorts hold a 0.59% of that float. The average trading volume for IRD on June 02, 2025 was 211.67K shares.
IRD’s Market Performance
IRD’s stock has seen a 14.64% increase for the week, with a 24.66% rise in the past month and a 20.32% gain in the past quarter. The volatility ratio for the week is 0.75%, and the volatility levels for the past 30 days are at 3.12% for Opus Genetics Inc The simple moving average for the past 20 days is 17.47% for IRD’s stock, with a 5.33% simple moving average for the past 200 days.
Analysts’ Opinion of IRD
Many brokerage firms have already submitted their reports for IRD stocks, with Craig Hallum repeating the rating for IRD by listing it as a “Buy.” The predicted price for IRD in the upcoming period, according to Craig Hallum is $6 based on the research report published on April 11, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see IRD reach a price target of $8. The rating they have provided for IRD stocks is “Buy” according to the report published on November 13th, 2024.
IRD Trading at 25.70% from the 50-Day Moving Average
After a stumble in the market that brought IRD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.36% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IRD starting from Magrath George, who purchase 100,000 shares at the price of $0.98 back on Dec 26 ’24. After this action, Magrath George now owns 599,150 shares of Opus Genetics Inc, valued at $97,600 using the latest closing price.
YERXA BENJAMIN R, the President of Opus Genetics Inc, purchase 10,000 shares at $0.98 during a trade that took place back on Nov 21 ’24, which means that YERXA BENJAMIN R is holding 342,800 shares at $9,834 based on the most recent closing price.
Stock Fundamentals for IRD
Current profitability levels for the company are sitting at:
- -5.65 for the present operating margin
- 1.0 for the gross margin
The net margin for Opus Genetics Inc stands at -5.23. The total capital return value is set at -2.43. Equity return is now at value -229.30, with -117.23 for asset returns.
Currently, EBITDA for the company is -57.52 million with net debt to EBITDA at 0.52. When we switch over and look at the enterprise to sales, we see a ratio of 3.21. The receivables turnover for the company is 1.9for trailing twelve months and the total asset turnover is 0.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.98.
Conclusion
In conclusion, Opus Genetics Inc (IRD) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
